Table 2. Impact of pneumococcal conjugate vaccine from different models, southern Israel*.
| Age group, mo. | Fit to 2004–05 through 2011–12 |
Fit to 2004–05 through 2010–11 (excluding 2011–12) |
|||||
|---|---|---|---|---|---|---|---|
| Full model | Model without RSV† | Unadjusted‡ | Full model | Model without RSV† | Unadjusted‡ | ||
| <6 | −31.5 (−50.6 to −14.5) | −30.7 (−57.2 to 9.7) | −20.0 (−70.2 to 76.5) | −27.9 (−62.9 to 9.2) | −5.2 (−68.5 to 83.9) | +22.3 (−81.5 to +106.0) | |
| 6–17 | −40.5 (−52.1 to −31.5) | −39.6 (−52.7 to −26.0) | −36.0 (−63.4 to 4.6) | −36.3 (−53.6 to −19.7) | −29.9 (−53.7 to –7.8) | −20.0 (−69.5 to +44.0) | |
| 17–35 | −33.6 (−41.5 to −25) | −33.0 (−40.9 tp −23.1) | −31.3 (−47.8 to −8.4) | −33.3 (−45.0 to −16.0) | −29.1 (−44.2 to –10.8) | −25.4 (−55.0 to +11.1) | |
*Vaccine impact is the estimated percentage change in disease incidence associated with pneumococcal conjugate vaccine use. RSV, respiratory syncytial virus. †Model fit with all predictors described in the methods section except for RSV activity. ‡Model fit with predictors for vaccine uptake and ethnicity only.